Literature DB >> 23861239

Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women.

Yan Tong1, Aaron Ermel, Wanzhu Tu, Marcia Shew, Darron R Brown.   

Abstract

Antibodies directed against the human papillomavirus (HPV) L1 protein are detected in approximately 70% of individuals with HPV infections. The factors associated with a serological response are not characterized. It is hypothesized that the HPV viral load, duration of detection, or both would be associated with seropositivity in adolescent women. Adolescent women (n = 117), ages 15-17 at enrolment were followed for a mean of 6.2 years. Quarterly vaginal swabs (mean 22 per participant) were used to identify HPV 6, 11, 16, or 18 DNA (Roche PCR/Linear Array). Type-specific HPV infection was defined as ≥2 positive assays. To approximate viral load, Roche PCR/Linear Array test strips were scored visually based on the strength of signal relative to beta-globin controls. Sera collected near the end of study were tested by cLIA. Regression models were fit to assess associations between strength of signal (as represented by mean and cumulative strength of signal), duration of HPV detection, seropositivity, and serotiter. Detection of HPV DNA was associated with seropositivity for four types combined and for types 6, 16, and 18. Overall, 70.1% of DNA positive episodes were associated with type-specific seropositivity. The cumulative HPV DNA signal strength during periods of HPV detection for types 6, 11, 16, and 18 combined was associated with seropositivity (OR = 1.21, 95% CI 1.02-1.44 P = 0.026). No other HPV DNA predictors were found to be associated with seropositivity or serotiter.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  adolescent women; antibody response; human papillomavirus

Mesh:

Substances:

Year:  2013        PMID: 23861239      PMCID: PMC4874647          DOI: 10.1002/jmv.23664

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  35 in total

1.  Sexual behavior among adolescent women at high risk for sexually transmitted infections.

Authors:  B P Katz; J D Fortenberry; W Tu; J Harezlak; D P Orr
Journal:  Sex Transm Dis       Date:  2001-05       Impact factor: 2.830

2.  Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women.

Authors:  L Wideroff; M H Schiffman; R Hoover; R E Tarone; B Nonnenmacher; N Hubbert; R Kirnbauer; C E Greer; A T Lorincz; M M Manos; A G Glass; D R Scott; M E Sherman; J Buckland; D Lowy; J Schiller
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

Review 3.  The known unknowns of HPV natural history.

Authors:  Patti E Gravitt
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

4.  Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.

Authors:  B Nonnenmacher; S Kruger Kjaer; E I Svare; J D Scott; N L Hubbert; A J van den Brule; R Kirnbauer; J M Walboomers; D R Lowy; J T Schiller
Journal:  Int J Cancer       Date:  1996-12-11       Impact factor: 7.396

5.  A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women.

Authors:  Darron R Brown; Marcia L Shew; Brahim Qadadri; Nicole Neptune; Maria Vargas; Wanzhu Tu; Beth E Juliar; Timothy E Breen; J Dennis Fortenberry
Journal:  J Infect Dis       Date:  2004-12-10       Impact factor: 5.226

Review 6.  The epidemiology of genital human papillomavirus infection.

Authors:  Helen Trottier; Eduardo L Franco
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

7.  Natural history of multiple human papillomavirus infections in female adolescents with prolonged follow-up.

Authors:  Bree Weaver; Marcia Shew; Brahim Qadadri; Wanzhu Tu; Yan Tong; Cheryl Denski; J Dennis Fortenberry; Darron Brown
Journal:  J Adolesc Health       Date:  2010-11-12       Impact factor: 5.012

8.  Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

Authors:  Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-02       Impact factor: 4.254

9.  Human papillomavirus infection and its association with cervical dysplasia in Ecuadorian women attending a private cancer screening clinic.

Authors:  C R Brown; M L Leon; K Muñoz; A Fagioni; L G Amador; B Frain; W Tu; B Qadadri; D R Brown
Journal:  Braz J Med Biol Res       Date:  2009-07       Impact factor: 2.590

Review 10.  Clinician's guide to human papillomavirus immunology: knowns and unknowns.

Authors:  Mark H Einstein; John T Schiller; Raphael P Viscidi; Howard D Strickler; Pierre Coursaget; Tina Tan; Neal Halsey; David Jenkins
Journal:  Lancet Infect Dis       Date:  2009-06       Impact factor: 25.071

View more
  13 in total

Review 1.  Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.

Authors:  Daniel C Beachler; Gwendolyne Jenkins; Mahboobeh Safaeian; Aimée R Kreimer; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2015-12-21       Impact factor: 5.226

2.  Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study.

Authors:  Shitaldas J Pamnani; Staci L Sudenga; Raphael Viscidi; Dana E Rollison; B Nelson Torres; Donna J Ingles; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Jorge Salmeron; Manuel Quiterio; Yangxin Huang; Amy Borenstein; Anna R Giuliano
Journal:  Cancer Res       Date:  2016-08-17       Impact factor: 12.701

3.  An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study.

Authors:  Daniel C Beachler; Ligia A Pinto; Troy J Kemp; Alan G Nyitray; Allan Hildesheim; Raphael Viscidi; John Schussler; Aimée R Kreimer; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-02-23       Impact factor: 4.254

4.  Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Authors:  Xavier Castellsagué; Paulo Naud; Song-Nan Chow; Cosette M Wheeler; Maria Julieta V Germar; Matti Lehtinen; Jorma Paavonen; Unnop Jaisamrarn; Suzanne M Garland; Jorge Salmerón; Dan Apter; Henry Kitchener; Julio C Teixeira; S Rachel Skinner; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Newton S de Carvalho; Klaus Peters; Wiebren A A Tjalma; Mahboobeh Safaeian; Alice Raillard; Dominique Descamps; Frank Struyf; Gary Dubin; Dominique Rosillon; Laurence Baril
Journal:  J Infect Dis       Date:  2014-03-08       Impact factor: 5.226

5.  Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.

Authors:  Louiza S Velentzis; Freddy Sitas; Dianne L O'Connell; Jessica Darlington-Brown; Sam Egger; Rohit Sinha; Emily Banks; Ian H Frazer; Karen Canfell
Journal:  BMC Infect Dis       Date:  2014-12-21       Impact factor: 3.090

6.  Redetection of human papillomavirus type 16 infections of the cervix in mid-adult life.

Authors:  Aaron Ermel; Marcia L Shew; Teresa M Imburgia; Matt Brown; Brahim Qadadri; Yan Tong; Darron R Brown
Journal:  Papillomavirus Res       Date:  2018-01-31

7.  Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies.

Authors:  Dominique Rosillon; Laurence Baril; Maria Rowena Del Rosario-Raymundo; Cosette Marie Wheeler; Susan Rachel Skinner; Suzanne Marie Garland; Jorge Salmeron; Eduardo Lazcano-Ponce; Carlos Santiago Vallejos; Tanya Stoney; Bram Ter Harmsel; Timothy Yong Kuei Lim; Swee Chong Quek; Galina Minkina; Shelly Ann McNeil; Celine Bouchard; Kah Leng Fong; Deborah Money; Arunachalam Ilancheran; Alevtina Savicheva; Margaret Cruickshank; Archana Chatterjee; Alison Fiander; Mark Martens; Marie Cecile Bozonnat; Frank Struyf; Gary Dubin; Xavier Castellsagué
Journal:  Cancer Med       Date:  2019-07-05       Impact factor: 4.452

Review 8.  The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.

Authors:  Anna Rosa Garbuglia; Daniele Lapa; Catia Sias; Maria Rosaria Capobianchi; Paola Del Porto
Journal:  Front Immunol       Date:  2020-02-18       Impact factor: 7.561

9.  Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study.

Authors:  Xingmei Yao; Wen Chen; Chao Zhao; Lihui Wei; Yuemei Hu; Mingqiang Li; Zhijie Lin; Bizhen Lin; Xiaohui Liu; Ying Hong; Qing Li; Qinjing Pan; Xun Zhang; Mingzhu Li; Yuqian Zhao; Li Zhang; Huifang Xu; Fangfang Hu; Jun Zhao; Yue Huang; Wei Sheng; Ya Zheng; Shangying Hu; Yingying Su; Shoujie Huang; Huirong Pan; Fanghui Zhao; Youlin Qiao; Ting Wu; Jun Zhang; Ningshao Xia
Journal:  Lancet Reg Health West Pac       Date:  2021-07-16

10.  Humoral Response to HPV16 Proteins in Persons with Anal High-Grade Squamous Intraepithelial Lesion or Anal Cancer.

Authors:  Helen C Stankiewicz Karita; Tim Waterboer; Amalia Magaret; David R Doody; Michael Pawlita; Nicole Brenner; Denise A Galloway; Anna Wald; Margaret M Madeleine
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-09-03       Impact factor: 4.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.